TABLE 1.

Characteristics of the Study Population.

Gender (n)	74% female (14), 26% male (5)
Mean age ± SD (Range)	78.0 ± 8.4 (63–92) Years
Naïve/Previously treated Eyes (n)	79% Eyes previously treated with IVT injections (15), 21% Treatment naïve eyes (4)
Previous IVT injections, Mean ± SD (Range) (Naïve patient excluded, n = 15)	47.2 ± 43.8 (4–139)
	14 eyes ranibizumab 25.0 ± 29.5 (3–98)
	9 eyes aflibercept 39.7 ± 32.5 (2–90)
Mean N° of IVT-B ± SD (Range)	3.0 ± 1.0 (2–6)
Mean follow-up time ± SD (Range)	14.4 ± 9.0 (4.0–35.8) Weeks

[SD, standard deviation; IVT, intravitreal; IVT-B intravitreal injection of brolucizumab].